However, when BP-1-102, a STAT3 inhibitor, was used, the expression levels of NRF2 and GPX4 were strikingly decreased, which reactivated ferroptosis and enhanced the sensitivity of osteosarcoma cells to cisplatin [135]. The gene discussed is STAT3; the disease is osteosarcoma.